Close Menu
iM.NewsiM.News

    Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    What's Hot

    Study: Escitalopram, Duloxetine Outperform Fluoxetine for Long-Term Depression

    November 21, 2026

    Curiosity Rover Captures Rare Twilight Clouds on Mars

    November 20, 2026

    US Lawmakers Seek Stricter AI Chip Export Controls

    November 20, 2026
    Facebook X (Twitter) Instagram
    iM.NewsiM.News
    Subscribe
    • Home
    • Lifestyle

      Study: Escitalopram, Duloxetine Outperform Fluoxetine for Long-Term Depression

      November 21, 2026

      US, Mexico, Bolivia Lose Measles-Free Status as Global Cases Rise

      November 20, 2026

      The Opera Coat Trend Takes Over Winter Fashion

      November 20, 2026

      New Weight-Loss Drug Cuts Knee Pain in Half for OA Patients

      November 20, 2026

      Robert Pattinson and Suki Waterhouse Redefine Hollywood Power Couples

      November 20, 2026
    • Relations

      US Lawmakers Seek Stricter AI Chip Export Controls

      November 20, 2026

      Trump Threatens Tax on US Tech Firms Building AI Data Centers Abroad

      November 20, 2026

      Former US National Security Adviser Jake Sullivan Confronted by Students at MIT

      November 20, 2026

      Xi Jinping’s Restraint: The Power of Not Acting in Shenzhen

      November 20, 2026

      EU and UK to Sign Reset Deal on Trade and Youth Mobility

      November 20, 2026
    • Technology

      Germany Proposes €25 Billion Buyout of TikTok Europe

      November 20, 2026

      AI Supply Chain Leaks 2 Million Secrets in Canary Test

      November 20, 2026

      Google to retire Nest app in January 2027

      November 20, 2026

      Microsoft Link to Windows Adds Second Screen Feature

      November 20, 2026

      Nothing Sets December 8 Date for AI Hardware Reveal

      November 20, 2026
    • Travel & Tourism

      TAP Air Portugal Adds Nonstop Porto Service from Washington Dulles

      November 20, 2026

      Oil Spills Threaten UAE and Oman Beaches Amid Hormuz Conflict

      November 20, 2026

      Aer Lingus to Retrofit A330 Fleet with Premium Economy and New Business Class

      November 20, 2026

      Sabre Targets AI Travel Bookings With New Connector

      November 20, 2026

      Riyadh Hotel Revenue Plummets 65% After Airport Attack

      November 20, 2026
    • Get in Touch
    iM.NewsiM.News
    Home»Lifestyle»Health»Study: Escitalopram, Duloxetine Outperform Fluoxetine for Long-Term Depression
    Health

    Study: Escitalopram, Duloxetine Outperform Fluoxetine for Long-Term Depression

    im.newsBy im.newsNovember 21, 2026No Comments3 Mins Read1 Views
    Facebook Twitter Pinterest LinkedIn Tumblr Email
    Pills for long-term antidepressants on a table
    Photo: Niels Heidenreich from Hannover, Germany / Wikimedia Commons, CC BY 2.0
    Share
    Facebook Twitter LinkedIn Pinterest WhatsApp Email

    A comprehensive review of clinical data indicates that certain antidepressants offer superior long-term benefits for patients managing depression. The analysis, published in The Lancet Psychiatry, found that escitalopram, duloxetine, and agomelatine were more likely to sustain symptom improvement over time compared to fluoxetine.

    Researchers also noted that patients taking escitalopram or duloxetine were less likely to discontinue their medication during the study period. These findings provide new context for a class of drugs that millions of people rely on for mental health stability.

    Comparing Medication Effectiveness

    The review analyzed data from 115 randomized controlled trials involving more than 30,000 participants. The researchers focused on long-term usage, defined as six months or more, to determine which medications helped people maintain their progress.

    Pills & drugs, healthcare photo
    Photo: Unknown / Rawpixel, CC0

    The main analysis combined results from 35 trials that directly compared one antidepressant against another. The data showed a clear advantage for escitalopram (Lexapro), duloxetine (Cymbalta), and agomelatine (Valdoxan) in terms of sustained response. Fluoxetine (Prozac) trailed these options in both symptom reduction and patient retention.

    Escitalopram is currently the most prescribed antidepressant in Australia, ranking 13th among all prescriptions dispensed through the Pharmaceutical Benefits Scheme in 2024-2025. Duloxetine ranked 45th, while agomelatine is not available on the scheme.

    Limitations and Real-World Usage

    Despite the promising results, the study authors cautioned that the findings are not definitive. More than half of the trials included in the main analysis were assessed as having a high risk of bias. This suggests that some of the observed differences between medications might reflect limitations in the original studies rather than genuine clinical superiority.

    Pills & drugs, healthcare photo
    Photo: Unknown / Rawpixel, CC0

    Additionally, the definition of long-term in these trials was relatively short. Most studies followed participants for about six months after they started medication. Only six trials tracked patients for longer than six months. This gap is significant because many Australians take antidepressants for much longer periods.

    Recent Australian data shows that nearly a quarter of people prescribed antidepressants were still receiving them two years later. Another study found the average duration of use is four years. Clinical guidelines recommend continuing treatment for at least six to 12 months after symptoms improve, but many patients stay on medication well beyond that window.

    The review highlights that individual responses to medication vary widely. A drug that works well for one person may cause unacceptable side effects for another. Factors such as previous medical history, other health conditions, and personal preferences play a major role in determining the best treatment path.

    counter medications can be most
    Photo: Unknown / Rawpixel, CC0

    Discontinuing antidepressants can also be challenging. Some patients experience withdrawal symptoms when trying to stop, which can make gradual reduction under medical supervision essential. The study notes that trial drop-out rates do not fully capture the complex trade-offs patients make between symptom relief and daily life impacts.

    For those currently taking an antidepressant that is working effectively, the study results do not suggest a need to switch medications. Patients considering starting, changing, or stopping their treatment should discuss their options with a doctor to ensure the best outcome for their specific situation.

    Source: ScienceDaily

    antidepressants depression Health Lexapro Medical Research Mental Health Prozac
    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
    Previous ArticleCuriosity Rover Captures Rare Twilight Clouds on Mars
    im.news

    Related Posts

    Curiosity Rover Captures Rare Twilight Clouds on Mars

    November 20, 2026

    US Lawmakers Seek Stricter AI Chip Export Controls

    November 20, 2026

    TAP Air Portugal Adds Nonstop Porto Service from Washington Dulles

    November 20, 2026
    Leave A Reply Cancel Reply

    Latest Posts

    Study: Escitalopram, Duloxetine Outperform Fluoxetine for Long-Term Depression

    November 21, 20261 Views

    Curiosity Rover Captures Rare Twilight Clouds on Mars

    November 20, 20262 Views

    US Lawmakers Seek Stricter AI Chip Export Controls

    November 20, 20263 Views

    TAP Air Portugal Adds Nonstop Porto Service from Washington Dulles

    November 20, 20262 Views
    Stay In Touch
    • Facebook
    • Twitter
    • Pinterest
    • Instagram
    • YouTube
    • Vimeo
    Don't Miss

    Epstein List Phase 1: Full Flight Logs, Client List Released

    February 28, 2025 News Focus 247 Views

    In a stunning development that has sent shockwaves through political and entertainment circles, Attorney General…

    Microsoft Stock Joins Exclusive $4 Trillion Club After Blockbuster Cloud + AI Earnings

    July 31, 2025

    DOJ & FBI Find No Epstein Client List, Suicide Confirmed

    July 7, 2025

    Subscribe to Updates

    Get the latest creative news from SmartMag about art & design.

    About Us
    About Us

    We provide the daily life news. You find latest trendy news at our portal, from entertainment to economy or politics.

    We're accepting new partnerships right now.

    Email Us: info@im.news

    Facebook X (Twitter) RSS
    Our Picks

    Study: Escitalopram, Duloxetine Outperform Fluoxetine for Long-Term Depression

    November 21, 2026

    Curiosity Rover Captures Rare Twilight Clouds on Mars

    November 20, 2026

    US Lawmakers Seek Stricter AI Chip Export Controls

    November 20, 2026
    Most Popular

    Epstein List Phase 1: Full Flight Logs, Client List Released

    February 28, 2025247 Views

    Microsoft Stock Joins Exclusive $4 Trillion Club After Blockbuster Cloud + AI Earnings

    July 31, 2025208 Views

    DOJ & FBI Find No Epstein Client List, Suicide Confirmed

    July 7, 2025165 Views
    © 2026 I'm News. Designed by I'm News.
    • Home
    • Lifestyle
    • Relations
    • Travel & Tourism
    • Technology

    Type above and press Enter to search. Press Esc to cancel.